PER 1.35% 7.5¢ percheron therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-28

  1. 720 Posts.
    lightbulb Created with Sketch. 210
    This interested me FWIW:

    A provisional patent application titled “Combination Compositions and Methods for Treatment of Muscular Dystrophy” has been filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs.

    A cursory delve into the current patent expiry of one exon skipping drug, Sarepta’s Exondys51, comes up with June 2025 as the patent expiry date, barring an extension.

    2044, or an added 19 years of potential protection, has got to be alluring, given 2 years of patent life remaining on Exondys51.
    Last edited by BoomCrashOffera: 17/04/23
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.5¢
Change
0.001(1.35%)
Mkt cap ! $67.61M
Open High Low Value Volume
7.7¢ 7.8¢ 7.4¢ $24.63K 325.4K

Buyers (Bids)

No. Vol. Price($)
2 142779 7.3¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 8181 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.